Engflag

Pentazole

Quick links to important sections

Pentazole

Pentazole_IT

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Pentazole

Property Description
Active Ingredients Mebendazole, Pantoprazole
Form Oral Tablet (Gastro-resistant)
Pharmacological Class Anthelmintic; Proton Pump Inhibitor (PPI)
Origin Synthetic
Type Fixed-Dose Combination (FDC)

Pentazole is the designated entity for a Fixed-Dose Combination (FDC) product containing the two distinct active ingredients, Mebendazole and Pantoprazole, in a single oral dosage unit. The unique feature of this preparation is its dual therapeutic action, integrating a compound for internal parasitic infections with a gastro-protective agent. The efficacy of both components has been established when used in combined therapies.

What Type of Medicine is Pentazole?

Pentazole is functionally classified by its two components: it is an Anthelmintic and a Proton Pump Inhibitor (PPI). The Mebendazole component belongs to the benzimidazole anthelmintic class, which is clinically recognized for its use in managing common parasitic infections. The Pantoprazole component is a synthetic substituted benzimidazole that acts as a potent anti-secretory agent. Proton pump inhibitors are characterized by their function of irreversibly suppressing the enzyme system responsible for gastric acid secretion.

This FDC status is a key differentiator, ensuring that the anti-parasitic agent and the acid-suppressor are delivered simultaneously to facilitate a comprehensive therapeutic outcome.

Composition and Dual Purpose

The core composition includes the Mebendazole and Pantoprazole International Nonproprietary Names (INN), formulated as an Oral Tablet. A critical differentiating factor for this FDC is the necessity for the tablet to be gastro-resistant. This specialized coating ensures the acid-sensitive Pantoprazole component is protected from degradation in the stomach, allowing it to be properly absorbed to initiate its anti-secretory effect.

The general purpose of this strategic pairing is to deliver a two-pronged approach. It is intended to interrupt the vitality of parasitic organisms while providing concurrent protection against the damaging effects of stomach acid. This combination is typically positioned for use in scenarios where managing both an internal parasitic burden and mitigating acid-related discomfort are required.

Regulatory References

  1. MedlinePlus Drug Information
  2. National Institutes of Health (NIH) confirms

What side effects are possible with Pentazole?

Possible Side Effects and Safety Information

The safety profile of Pentazole is officially documented through the combined adverse reaction classifications of its two active components, Mebendazole and Pantoprazole. These reactions are categorized according to frequency and affected body systems, as defined in regulatory labeling.

Commonly Documented Adverse Reactions

The most frequent effects, classified as Common in regulatory documents, primarily include Gastrointestinal Disorders such as abdominal pain, diarrhea, flatulence, nausea, and vomiting. Headache is also commonly listed under Nervous System Disorders.

Rare and Serious Adverse Reactions

Regulatory sources explicitly define serious, though Rare, adverse reactions. These include severe Hypersensitivity Reactions (e.g., anaphylactic shock, angioedema), blood disorders (such as agranulocytosis), and severe Cutaneous Reactions (including Stevens-Johnson syndrome and Toxic Epidermal Necrolysis). Rare Hepatobiliary Disorders, like hepatitis and jaundice, are also documented.

Duration and Population-Specific Safety Notes

Specific safety concerns are associated with the duration of use. Prolonged exposure is linked to an increased risk of bone fractures of the hip, spine, or wrist, and the development of Hypomagnesemia (low magnesium levels). Fundic Gland Polyps may also occur with prolonged use. Furthermore, regulatory labels advise caution and monitoring in patients with severe hepatic impairment, while also noting the risk of convulsions in very young children with significant parasitic burden.

Overdose and Emergency Response

Overdose and when to seek help

Overdose involving Pentazole requires immediate medical attention based on the documented risks associated with its two components. The official regulatory profile for Pentazole notes that an overdose of the Mebendazole component may present with gastrointestinal symptoms, including abdominal cramps, nausea, vomiting, and diarrhoea. While overdose experience with the Pantoprazole component is officially noted to remain generally within the known safety profile, all suspected overdose cases must be assessed by a healthcare professional.

Crucially, in scenarios involving substantially high overexposure or prolonged use of Mebendazole, the regulatory documents describe the potential for severe systemic outcomes affecting the hematologic (e.g., agranulocytosis, neutropenia), hepatic, and renal systems.

Because no specific antidote is known for the Mebendazole component, regulatory guidance explicitly states that if an overdose is suspected or confirmed, individuals must seek immediate medical attention or call a Poison Control Center. Emergency services must be contacted immediately if severe manifestations, such as collapse, seizure, or breathing difficulties, are present. Management is required to be symptomatic and supportive, and official procedures may include the use of activated charcoal to remove unabsorbed drug. It is also noted in official labeling that the Pantoprazole component is not removed by hemodialysis.

Therapeutic Uses of Pentazole

What Pentazole Treats: Main Uses and Benefits

This medication, containing two active components, is applied across two distinct therapeutic domains. The utility of this combination focuses on the therapeutic domain of anti-parasitic action while managing acid-related issues. The primary therapeutic use is commonly used to help with susceptible intestinal parasitic infections such as those caused by roundworm, hookworm, whipworm, and pinworm. Concurrently, it supports general well-being by managing conditions like Gastroesophageal Reflux Disease (GERD) and may be part of symptomatic management for Erosive Esophagitis.

It is commonly used to help with symptoms related to physical discomfort from parasitic conditions and frequent or more noticeable heartburn and acid regurgitation associated with GERD. This medication plays a role in managing symptoms related to systemic imbalance across two therapeutic domains.

Quick Fact: Relief for Dual Discomfort

Quick Fact: Relief for Dual Discomfort This FDC is relevant in contexts where a patient requires management of intestinal parasitic conditions and concurrent supportive symptom management for recurrent heartburn. It helps maintain a sense of stability when symptoms are more noticeable.

Eligibility and Restrictions for Use

Pentazole (Pantoprazole) is generally indicated for adults and children aged five years and older to manage conditions associated with excess stomach acid, such as erosive esophagitis associated with Gastroesophageal Reflux Disease (GERD) and pathological hypersecretory conditions like Zollinger-Ellison syndrome.

Contraindications and Restricted Use

The medication is contraindicated for patients with a known hypersensitivity or allergic reaction to any of its components or to other substituted benzimidazoles. It should also not be used concurrently with certain antiretroviral drugs, specifically those containing rilpivirine.

Patient Group Consideration for Use
Children under 5 years Safety and efficacy are not established for children younger than five years of age.
Pregnancy Use is generally not recommended unless the potential benefit outweighs the unknown risk to the fetus.
Breastfeeding Use should be approached with caution, as the drug passes into breast milk.
Existing Conditions Patients with pre-existing liver disease, a history of Systemic Lupus Erythematosus (SLE), a high risk of bone fracture, or conditions involving low magnesium in the blood (hypomagnesemia) require close monitoring. The presence of a gastric malignancy must be ruled out before starting treatment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Regulatory Prohibitions and Contraindications

The regulatory labeling identifies medicines that should not be co-administered. The Mebendazole component is avoided with Metronidazole due to the documented risk of severe skin reactions. The Pantoprazole component is contraindicated with Atazanavir and Nelfinavir, as co-administration significantly reduces the plasma concentrations of these medicines, leading to loss of therapeutic effect.

Pharmacokinetic and Exposure Modification

The profile details changes in drug exposure. CYP enzyme inducers like Carbamazepine or Phenytoin may decrease the systemic exposure of the Mebendazole component. The Pantoprazole component’s pH-elevating effect reduces the absorption of medicines requiring gastric acid, including Ketoconazole, Itraconazole, and Erlotinib. The Pantoprazole component is also documented to increase the serum concentration of Methotrexate and requires INR monitoring when co-administered with Warfarin.

Procedural and Population Notes

The Pantoprazole component interferes with certain diagnostic tests, causing false-positive results in urine screens for THC. It also requires temporary cessation before CgA neuroendocrine tumor testing. For patients with Hepatic Impairment, official documents note that the systemic exposure of the Mebendazole component may be higher. Food co-administration does not alter the overall extent of absorption of the Pantoprazole component.

Mechanism of Action

Irreversible Blocking of the Gastric Proton Pump

Pentazole functions as an irreversible inhibitor of the H^+/ K^+- ATPase (proton pump), the terminal enzyme responsible for acid secretion in gastric parietal cells. The drug is a prodrug that becomes chemically activated only in the highly acidic environment of the cell's canaliculi. Once activated, it forms a permanent covalent bond with cysteine residues on the pump's surface, thereby physically stopping the enzyme from exchanging hydrogen ions ( H^+) for potassium ions ( K^+).

Modulating the Acid Secretion Cascade

This targeted inactivation of the pump leads to a profound and sustained suppression of gastric acid output. The mechanism ensures that the reduction in acidity is substantial, resulting in altered acid-base conditions for the gastric and esophageal mucosa. Additionally, Pentazole is associated with the secondary inhibition of the DDAH1 enzyme, which may influence the regulation of vasoactive mediators and result in modulation of vascular tone independent of its primary gastric mechanism.

Dosage and Administration Information

Pentazole is a Fixed-Dose Combination (FDC) medicine administered exclusively by the oral route as a gastro-resistant tablet. The specialized formulation dictates that the tablet must be swallowed whole with water and must not be chewed, crushed, or split under any circumstances, a requirement relating to the stability requirements of the Pantoprazole component. The administration timing is typically one hour before a meal to ensure proper effect of the acid-suppressing agent.

Dosing and Frequency Patterns

The usage pattern for Pentazole is structured to address the dual therapeutic components, resulting in both short-term and longer-term regimens.

Usage Type Component Focus Standard Adult Dosing & Frequency
Anthelmintic Course (Short-Term) Mebendazole 100 mg twice daily for three consecutive days (for certain infections), or a 100 mg single dose (for pinworm).
Gastro-Protective Use (Sustained) Pantoprazole 40 mg once daily for the maintenance of healing of erosive esophagitis. This regimen may be continued for up to eight weeks or longer depending on the clinical context.

If the initial anthelmintic course is unsuccessful, the regimen may be repeated after two to three weeks. While no dose adjustment is required for older adults or in patients with renal impairment, individuals with severe hepatic impairment require a reduction in the Pantoprazole dose, typically not exceeding 20 mg once daily.

Recent Clinical Evidence

Research evidence / Overview of studies for Pentazole

The research evidence for Pentazole, a fixed-dose combination product, is based primarily on clinical studies conducted on its two separate active components: an anti-parasitic agent (Mebendazole) and an acid-suppressing agent (Pantoprazole). Dedicated research on the combination in a single tablet is an area of study that remains limited.

Evidence for Managing Intestinal Parasitic Infections

Research exploring the anti-parasitic component was evaluated in settings that included Randomized Controlled Trials (RCTs) and comparative efficacy trials. These studies focused on populations diagnosed with conditions associated with acute or disruptive episodes caused by common intestinal roundworms and pinworms. Researchers primarily examined outcomes related to parasitological cure rate and the egg reduction rate.

The findings describe patterns observed in the studies where participants showed measurements of clearance of parasite eggs after receiving the treatment course. Long-term effects are not fully established regarding the recurrence of parasitic infections following treatment. Furthermore, data for certain groups remain insufficient, particularly formal trial data for very young children (infants and children under two years).

Evidence for Managing Acid-Related Conditions

The research base for the acid-suppressing component was evaluated in clinical trials including multicenter, randomized, placebo-controlled Phase III clinical trials, followed by systematic reviews and meta-analyses. These studies were relevant in trials assessing short-term or episodic symptom patterns and outcomes linked to inflammatory or irritative states such as Erosive Esophagitis (EE).

Studies reported measurements of mucosal healing confirmed by endoscopy after short-term treatment courses. The research also describes patterns where the component was observed in studies examining the outcomes related to physical discomfort during extended observation periods. Long-term effects are not fully established for all aspects of use, with follow-up durations limited in some trials regarding how long outcomes related to physical discomfort lasts following treatment discontinuation.

Key Research Gaps and Areas of Uncertainty

A significant limitation identified in the evidence base is the research base of the Fixed-Dose Combination (FDC) product itself. While the two components have established research profiles individually, comparative evidence is lacking for the specific Pentazole FDC tablet. Dedicated clinical trials remain necessary to assess whether the simultaneous delivery of Mebendazole and Pantoprazole in a single unit performs comparably to giving the two medicines separately. Data are still emerging concerning the research exploring short-term symptom changes of the acid-suppressing component on the anti-parasitic component's physiological response.

Key Studies & References

  1. Mebendazole - StatPearls - NCBI Bookshelf - NIH (General Mebendazole Monograph/Indications)
  2. Hypertension: Developing Fixed-Combination Drug Products for Treatment - HHS.gov (General FDC Clinical Trial Guidance)

Frequently Asked Questions (FAQ)

Common questions about Pentazole (FAQ)

Q: What is Pentazole used for?

According to official product information, Pentazole is used to treat conditions caused by excessive stomach acid production. This includes conditions like gastroesophageal reflux disease (GERD), which causes heartburn, and healing erosions of the esophagus. It is also indicated for managing conditions that require a reduction of acid for healing, such as certain stomach ulcers.

Q: How long does it take for Pentazole to start working?

Official information indicates that while Pentazole may begin to reduce acid production within a few hours of the first dose, the full therapeutic benefit may not be felt immediately. For certain conditions, such as the healing of erosions, it can take several weeks of consistent use to achieve complete relief and healing, as stated in regulatory documents.

Q: Can I stop taking Pentazole when my symptoms improve?

Regulatory documents suggest that the duration of treatment with Pentazole depends on the specific medical condition being treated. For full effectiveness and to prevent symptoms from returning, following the complete prescribed course is generally recommended, even if symptoms improve quickly. Any changes to the treatment plan should be discussed with a healthcare provider.

Q: What should I do if I miss a dose of Pentazole?

Regulatory product information typically contains instructions for managing a missed dose, such as taking it as soon as it's remembered, unless it is nearly time for the next scheduled dose. If it is nearly time for the next dose, the missed dose is usually skipped, and the regular schedule is continued. Official guidance advises against taking a double dose to compensate for the one that was missed.

Q: Is Pentazole safe for long-term use?

Studies and official information indicate that Pentazole is safe and effective when used as directed for the specified duration of treatment. For some conditions, long-term use (e.g., beyond one year) may be indicated. Regulatory documents suggest that prolonged use often involves periodic monitoring by a healthcare provider.

Q: Can Pentazole be taken with food?

The official product information for Pentazole states that the medicine can be taken with or without food. This flexibility means its effect is generally not dependent on the timing of meals. It is important to swallow the tablets whole with liquid, as specified in the preparation instructions.

How should Pentazole be stored and disposed of?

Pentazole must be stored in its original container at room temperature, which should be kept away from excessive heat, moisture, and direct light. It is essential to keep the medication in a secure, closed container, out of the reach of children and pets. Do not store this medication in the bathroom.

Disposal of Unused Medication

When disposing of pentazole, do not flush the medication down a toilet or pour it down a drain unless specifically instructed to do so by a healthcare professional or an official drug take-back program. Expired or no longer needed medication should be disposed of properly. The best way to dispose of unused medication is through a local drug take-back program. If a take-back program is unavailable, consult with a pharmacist or local waste disposal company for guidance on environmentally safe disposal methods.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Pentazole found in:

A-Z Index: